Cerebral Vasospasm
1
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 3 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Temple TherapeuticsNetherlands - Geleen
1 program1
NicardipinePhase 4Small Molecule1 trial
Active Trials
GenomicsUK - Oxford
1 programIdentification of Novel Molecular Markers for VasospasmN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Temple TherapeuticsNicardipine
VesalioNEVA VS
VesalioNeVa VS
GenomicsIdentification of Novel Molecular Markers for Vasospasm
Clinical Trials (4)
Total enrollment: 372 patients across 4 trials
The Intra-arterial Vasospasm Trial
Start: Aug 2016Est. completion: Aug 202492 patients
Phase 4Terminated
Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts
Start: Apr 2025Est. completion: Mar 2027200 patients
N/ARecruiting
Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)
Start: Dec 2018Est. completion: May 202130 patients
N/ACompleted
Identification of Novel Molecular Markers for Vasospasm
Start: Sep 2010Est. completion: Oct 201950 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 372 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.